Myriad Genetics Inc
$ 5.00
-3.66%
16 Apr - close price
- Market Cap 490,159,000 USD
- Current Price $ 5.00
- High / Low $ 5.30 / 4.97
- Stock P/E N/A
- Book Value 3.94
- EPS -3.95
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.08 %
- ROE -0.24 %
- 52 Week High 8.59
- 52 Week Low 3.76
About
Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
Analyst Target Price
$7.78
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-23 | 2025-11-03 | 2025-08-05 | 2025-05-05 | 2025-02-25 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-06 | 2023-08-03 | 2023-05-03 |
| Reported EPS | 0.04 | -0.2943 | 0.05 | -0.03 | 0.03 | 0.06 | 0.05 | -0.01 | 0.04 | -0.03 | -0.08 | -0.21 |
| Estimated EPS | -0.0172 | -0.01 | -0.01 | -0.0544 | 0.0303 | 0.02 | -0.01 | -0.1 | 0.01 | -0.08 | -0.08 | -0.19 |
| Surprise | 0.0572 | -0.2843 | 0.06 | 0.0244 | -0.0003 | 0.04 | 0.06 | 0.09 | 0.03 | 0.05 | 0 | -0.02 |
| Surprise Percentage | 332.5581% | -2843% | 600% | 44.8529% | -0.9901% | 200% | 600% | 90% | 300% | 62.5% | 0% | -10.5263% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.17 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $1.75 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MYGN
2026-04-16 17:09:36
Myriad Genetics Inc (MYGN) announced it will present six research abstracts, including two significant podium presentations, at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The company will showcase advancements in its minimal residual disease (MRD) and hereditary cancer initiatives, reinforcing its leadership in molecular diagnostics. Despite a moderate GF Score™ of 57/100 and recent insider buying, MYGN faces profitability challenges with negative earnings, trading below its 52-week high.
2026-04-16 13:09:36
Myriad Genetics will present six abstracts, including two podium presentations, at the American Association for Cancer Research (AACR) Annual Meeting on April 17-22, 2026. The presentations will cover new findings from the MONITOR-Breast study on ctDNA dynamics in breast cancer and results from a phase II clinical trial on PD-1 blockade. Myriad will also showcase its Precise MRD assay, MyRisk Hereditary Cancer Test with RiskScore, Prolaris, MyChoice CDx, and biopharma partnership offerings.
2026-04-16 13:09:36
Myriad Genetics, Inc. will present six abstracts, including two podium presentations, at the American Association for Cancer Research (AACR) Annual Meeting 2026. This includes new data from the MONITOR-Breast study demonstrating the performance of Precise MRD™ in breast cancer across various treatment phases. The company aims to highlight advancements in its tumor-informed, ultrasensitive MRD assay and hereditary cancer programs, providing insights into personalized treatment decisions for cancer patients.
2026-04-15 23:09:36
Myriad Genetics (NASDAQ:MYGN) experienced a 25.1% decline in short interest during March, with total short interest falling to 8,763,576 shares as of March 31st. This equates to approximately 9.6% of shares sold short and a days-to-cover ratio of 2.9. Despite a consensus "Hold" rating from analysts and insider purchases, the company remains unprofitable with a negative net margin.
2026-04-15 20:09:04
Myriad Genetics' Chief Scientific Officer, Dale Muzzey, had 946 shares of common stock withheld by the company to cover tax obligations related to vesting restricted stock units. This transaction, reported on April 14, 2026, at a price of $4.91 per share, is a routine tax-withholding event, not a sale. After this, Muzzey directly holds 326,310 shares of Myriad Genetics common stock.
2026-04-15 20:09:04
Myriad Genetics COO Mark Verratti had 1,069 shares of company stock withheld to cover tax obligations from vested restricted stock units. The shares were valued at $4.91 each, and this transaction was a routine tax disposition, not an open-market sale. Verratti still directly holds 629,646 shares of Myriad Genetics common stock after this withholding, indicating it was a small portion of his total equity.
